Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form

The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elía et al., p. 866. ©2022 American Association for Cancer Research.

Citation

Carlos Ronchi, Cathrin Brisken. Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Mar 01;29(5):833-834

Mesh Tags

Substances

PMID: 36547665

search → result